Oncotarget

Research Perspectives:

Latest progress in tyrosine kinase inhibitors

Tatiana V. Pospelova _ and Valery A. Pospelov

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:1157-1161. https://doi.org/10.18632/oncotarget.1836

Metrics: PDF 1155 views  |   HTML 1513 views  |   ?  


Abstract

Tatiana V. Pospelova1,2 and Valery A. Pospelov1,2

1 Institute of Cytology, Russian Academy of Sciences, St. Petersburg, Russia

2 Saint Petersburg State University, St. Petersburg, Russia

Correspondence:

Tatiana V. Pospelova, email:

Keywords: cancer, mTOR, kinases, c-Met, Bcr-Abl, senescence

Received: March 10, 2014 Accepted: March 20, 2014 Published: March 20, 2014

Abstract

Here we discuss the latest progress in development of some kinase inhibitors such as inhibitors of c-MET, LIM and Bcr-Abl kinases. Importantly, many oncogenic kinases signal via the mTOR pathway, suggesting a common target for drug combinations.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1836